Immediate-type Allergy in vivo and in vitro
The anaphylactic mechanism (immediate-type, or Type I, Gell & Coombs 1968) , is schematically represented in Fig 1. Anaphylactic antibodies (mainly IgE in man) get fixed to 'receptor sites' on the surface of tissue mast cells and basophil leukocytes, thus sensitizing them. These sensitized cells upon subsequent interaction with the allergen release pharmacological mediators, which produce the clinical manifestations of allergy through their action on effector cells in various tissues, e.g. bronchial and vascular smooth muscle. This type of allergic reaction may be prevented or treated by various pharmacological means. For example, bronchial asthma due to immediate-type allergy to various allergens may be treated by: (1) bronchodilators acting directly on bronchial smooth muscle, thus acting as 'physiological' antagonists; (2) competitive and nonspecific antagonists of the pharmacological mediators *------------Mediators inhibitor of specific physiological mediator release antagonist antagonist of mediator released in this type of reaction represented, for example, by antihistamines and anti-inflammatory drugs respectively; (3) inhibitors of the anaphylactic mechanisms acting by suppression of the release of these mediators. It should be realized that the allergen not only produces mediator release but may also stimulate its formation, e.g. we have shown that allergen challenge increases the histamine-forming capacity (HFC) of sensitized leukocytes both in vitro and in vivo (Assem, Schild & Vickers 1972) , and this may lead yet to another approach to the inhibition of immediate-type allergy, namely through inhibition of mediator synthesis. Some compounds like beta-adrenoceptor stimulants have at least a triple effect: (I) relaxation of bronchial smooth muscle;
(2) prevention of mediator release (Assem & Schild 1969) ; (3) more recently we have shown (Assem & Feigenbaum 1972 ) that ,B-adrenoceptor stimulants also inhibit histamine formation via their effect on the histidine decarboxylase system (Fig 2) . Another compound, disodium cromoglycate (Fisons Pharmaceuticals), apparently only inhibiting mediator release, is now widely used as a protective drug in bronchial asthma (Altounyan 1967 , Cox 1967 , Pepys et al. 1968 , Assem & Mongar 1970 . There are several other compounds which can inhibit the anaphylactic mechanism, but they either can- Assem & Schild 1969 , Assem & Mongar 1970 . Leukocytes play a prominent role in allergic and inflammatory reactions (Janoff 1970) . Therefore, it seems that the development of new compounds which are effective in this respect might be of value in the treatment of allergic conditions. We have had an opportunity to investigate a new series of compounds produced by Allen & Hanburys Limited. including AH 6556 and AH 7079, which seem to be promising in this respect, since apart from their potency as inhibitors in various in vivo and in vitro model systems for immediate-type allergy, they are particularly potent in inhibiting allergeninduced histamine release from leukocytes isolated from the blood of allergic human subjects. They also have some inhibitory effect on allergeninduced stimulation of sensitized human lymphocytes (blast transformation, mitosis and DNA synthesis). A further member of this series is AH 7725, which seems to offer additional advantages (Fullarton et al. 1973) . The structural formulas of these three compounds are shown in Model Studies ofInhibitors of Immediate-Type Allergy Since the introduction of disodium cromoglycate (DSCG) great experience has been acquired, and a marked improvement in the techniques of assessing drugs of this type has taken place. It is Section ofClinical Immunology & Allergy 1193 my intention in this paper to discuss our investigation of the AH series (AH 7079 and AH 6556) and comparison of them with DSCG, both in vivo and in vitro, as an illustration of these improved techniques. Our investigation followed the initial screening and studies in experimental animals in vivo. This in vivo work included two models for immediatetype allergy in the rat, namely passive cutaneous anaphylaxis and passive intraperitoneal anaphylaxis. The in vitro and in vivo tests used in our studies will be discussed in that order, with greater emphasis in this paper on the in vivo studies in patients with allergic airways disease. This study, apart from showing the difference in the relative potencies of these various compounds in several test models, has clearly shown how difficult it may be to express this in the commonly used potency ratios, due mainly to the frequent irregularity and irreproducibility in the shape of dose-response curves. The value of studies, using the traditional pharmacological technique of obtaining dose-response curves with these inhibitors will become apparent.
Invitro Models
Only a brief summary of this will be given in this paper; further details are published elsewhere .
(a) Antigen-induced histamine-release from human lung passively sensitized by preincubation with serum from patients with respiratory allergy due to house-dust mite Dermatophagoides pteronyssinus (Assem & Schild 1968 , Assem & McAllen 1970 was inhibited by AH 6556, AH 7079 and disodium cromoglycate (DSCG). In this system 50 % inhibition was obtained by concentrations of the order of 10-4M. On the whole, AH 7079 was slightly more potent than AH 6556, and both were more potent than DSCG, but potency ratios could not be calculated because of the previously mentioned reasons. 'Reversed' anaphylaxis in which histamine release is produced by challenge with antihuman IgE serum (Lichtenstein et al. 1970 ) was similarly inhibited by these compounds.
(b) Leukocytes isolated from blood of allergic patients develop a strong reaction to antigen, and thus may release their histamine (Lichtenstein & Osler 1964 , Assem & McAllen 1970 . In our laboratory the effect of inhibitors is usually tested in the presence of suboptimal antigen concentrations. In the results reported here, these antigen concentrations released 40-50% of total cell histamine in the absence of inhibitors (uninhibited release). Control aliquots of leukocytes (unchallenged with antigen) usually released a small amount of histamine (1-5 %). In general, there is an inverse relationship between the levels of uninhibited histamine release, which depends on antigen concentration, and the percentage reduction of this release obtained by various inhibitors. In this leukocyte preparation the potency of the new AH compounds was compared not only with DSCG, but also with that of a large number of compounds belonging to various groups of inhibitors. This included ,B-adrenoceptor stimulants (which seem to exert their effect through stimulation of adenyl cyclase), theophylline and other phosphodiesterase inhibitors, including the new ICI derivatives 30966 and 58301 (Davies et al. 1971) , and dibutyryl cyclic adenosine 3',5'-phosphate (Calbiochem).
Beta-adrenoceptor stimulants were the most potent of all these inhibitors. The Allen & Hanburys compounds were next in potency, followed by the ICI phosphodiesterase inhibitors. Disodium cromoglycate was the least potent among all these compounds. Concentrations of isoprenaline producing 50 % inhibition of a histamine release of nearly 50% of the total cell content varied between 10-6 and 10-5M (Assem & Schild 1971a) . A similar degree of inhibition was obtained with a concentration of the order of 10-4M of AH 7079, the more potent of the two Allen & Hanburys compounds (compared with AH 6556). By contrast with this relative potency in the leukocyte preparation, AH 7079 was at least 1000 times less potent than isoprenaline in the lung preparations.
The comparison between DSCG and AH 7079 and AH 6556 is shown in Fig 4. when the antigen concentration is well below optimum concentration (Assem & Mongar 1970) .
The results suggest that AH 7079 is at least 100 times more potent than DSCG in the human leukocyte preparation. By comparison with in vivo screening tests and other in vitro tests (with the exception of the lymphocyte transformation tests) this model shows AH 7079 to have a high degree of superiority.
(c) Histamine release from actively and passively sensitized guinea-pig lung, using in the latter specifically purified yt antibodies against dinitrophenol (DNP) (Assem & Mongar 1970) : All the three compounds tested produced inhibition of antigen-induced histamine release from actively and passively sensitized guinea-pig lung preparations. AH 7079 and AH 6556 seemed to be equipotent (thus slightly different from human lung), but both compounds were again more potent than DSCG.
(d) Histamine release from isolated peritoneal mast cells of sensitized rats (Perera & Mongar 1963): In vitro antigen-induced histamine release from isolated mast cells can be partially inhibited by AH 7079, AH 6556 and DSCG, but the inhibition is not obtained as readily or as regularly as in the in vivo passive intraperitoneal anaphylaxis. Both AH 7079 and AH 6556 were slightly more potent than DSCG, and all exhibited an optimum concentration of the order of 10-4M which, when exceeded, showed a reduction in the inhibition of histamine release.
(e) Histamine release from isolated rat peritoneal mast cells by the mast-cell degranulating peptide (MCDP 401) in the venom of the honey bee (Assem & Atkinson 1973 ): In this model, direct Table I release of histamine was inhibited by DSCG, AH 6556, AH 7079 and AH 7725. However, their relative potency in this model differed from that in the antigen-induced response; e.g. DSCG was more potent than AH 7079, but AH 7725, which has most of the advantages of its predecessors plus the additional advantage of potential use by mouth, was slightly more potent than DSCG.
(f) Lymphocyte stimulation (transformation) test (Chalmers et al. 1967) , an in vitro correlate of cell-mediated immunity (delayed-type hypersensitivity): Sensitized human lymphocytes isolated from the blood of two patients were stimulated by antigen (tuberculin PPD, Evans Medical Limited, or grass pollen) as shown by an increase in incorporation of tritiated thymidine. This response was inhibited by AH 7079. This compound, however, did not inhibit DNA synthesis in unstimulated lymphocytes, indicating a selective effect. AH 7079 was more potent than AH 6556; DSCG, on the other hand, did not produce any significant inhibition.
In vivo Model Studies in Allergic Airways Disease Twelve patients (7 women and 5 men) aged 20 to 55 years, all suffering from allergic asthma, were included in the quantitative studies of the protective effects of DSCG and AH 7079 on the bronchial response to inhalation of allergen (house-dust mite D. pteronyssinus in 9 patients and grass pollen in 3). Thirty-three patients (17 females and 16 males, aged 14-55), including 3 from the previous group, were included in the investigation of the protective effect of AH 7079 in nasal challenge tests. Twenty-two of these patients suffered from grass pollen allergy, and 13 were allergic to D. pteronyssinus. (Herxheimer 1951 , McAllen 1961 . The methods of exposure to different doses of allergen extracts are described elsewhere , Assem & McAllen 1973 . In all 12 patients bronchial challenge with antigen produced immediate-type reactions manifested by reduction in ventilatory function as shown by reduction in forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and expiratory peak flow rate (EPFR) occurring within 10-15 minutes. In 5 of these patients late reactions (after 1-24 hours or longer) also occurred. These later reactions were measured by changes in EPFR, using a Wright peak-flow meter. In order to ascertain the causal relationship between these reactions and the bronchial provocation tests, these patients were asked to keep a regular record of their EPFR and of their bronchodilator requirement.
The method for introduction of various doses of aerosolized solutions of DSCG and AH 7079, and placebo, over a nearly fixed time into the closed circuit has been described elsewhere (Assem & McAllen 1973) . These aerosols were inhaled two minutes before antigen challenge.
The tests were repeated once or twice a week.
Although initial tests were carried out with single-dose challenge, on subsequent occasions when this dose failed to elicit a reaction (either due to protection by drugs or development of desensitization) further doses were given. Thus some patients were given up to four test doses in sequence. In this way tolerance, apart from being expressed by reduction in response to a standard dose of antigen, may also be expressed in terms of the amount of antigen which has to be given in order to achieve the pretolerance response. By studying both antigen dose-response curves (carried out by the latter and/or previously described method) in absence or presence of various inhibitor concentrations, with the consequent possibility of applying various statistical analyses, we may be in a position to claim the most accurate assessment so far of the effects of these drugs. These studies are also unique in showing the limitations of relatively simple procedures, and of empirical choice of drug doses for testing, as well as for therapy. AH 7079 reduced or completely prevented asthmatic attacks induced by inhalation of antigen in 7 of the 12 patients. None suffered irritation of airways or other noticeable side-effects. Special care was required to avoid artifacts produced by bronchial hyposensitization and variability in the degree of response to antigen. This (1) Both drugs produced 'unusual' doseresponse curves, thus making the assessment oftheir relative potency virtually impossible. (2) Maximum protection with AH 7079 was obtained with 3 mg doses in both patients, while DSCGproduced maximum protection in doses of3 mg and I mg respectively. An increase in dosage ofeither drug above these levels produced an unexpected reduction in protection.
(3) Although in the secondpatient maximum inhibition with DSCG was obtained with a smaller dose than requiredfor maximum inhibition with AH 7079, the degree ofinhibition with DSCG was smaller than with AH 7079 . Note that the usual optimal dose ofAH 7079 (3 mg) produced markedprotection in the bronchial challenge test, while DSCG had no significant protective effect over a wide dosage range, AH 7079 or disodium cromoglycate were used were alternated with those with antigen only or placebo pretreatment. Examples of the protective effect of AH 7079 are shown in Fig 5. The effect ofAH 7079 in 3, 4 and 8 mg doses was statistically significant (P<0.02) (Table 1 ). An attempt was made to obtain dose-response curves for AH 7079, and to compare it with disodium cromoglycate, but there were some limitations, such as the number of possible tests before the onset of desensitization, and the caution required in dosage of the new drug.
The relative potency of these two compounds was assessed quantitatively in two patients (AS and BC) using two or more doses of each drug. Thus proper dose-response curves were obtained (Table 1 and Fig 5) . Patient AS had six tests with antigen alone, with and without placebo treatment, five tests with AH 7079 and two tests with DSCG. On most occasions, after thus illustrating a clear example ofthe individual variability in response to these two inhibitors. Below, failure ofsingle doses ofthe above-mentioned drugs inpreventing late reactions to bronchial challenge measuring the response to 60,g doses of antigen, he was given a further test with 30 ug doses, and shifts of these antigen dose-response curves were obtained by both drugs. In both patients protection was obtained with 3 mg doses of AH 7079, and smaller doses produced progressively smaller effects. In these two patients there seemed to be no advantage in giving higher doses of AH 7079. In fact, the latter treatment produced a slight reduction in the protective effect. On the other hand DSCG produced complete protection in patient AS at the lower dose (3 mg) but little effect at 6 mg, and also produced substantial protection at 1 mg dose, but not at 3 mg in patient BC (i.e. there are some similarities in the pattern of inhibition with that of AH 7079). This individual variability in optimal doses is compatible witb unpublished clinical observations (Dr A W Frankland). Although within the dose range of 3-8 mg of AH 7079 (three observations), the protective 
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Antigen 0 effect in patient AS was statistically significant (P<0.02), while with 3-6 ng DSCG (two observations) it was not significant, the calculation of the relative potency of these compounds was not possible (Table 1) .
Apart from the individual variation in the optimum dosage of the different inhibitors, as has been mentioned previously, which may be interpreted as differences in their relative effectiveness in certain patients, one inhibitor may completely fail (over a wide dose range) to inhibit the response to bronchial challenge, while the other remains effective in the 'usual' dosage. For example, in one patient (AG) 3 mg of AH 7079 produced marked protection. On the other hand, DSCG (even with a dose up to 20 mg) produced little or no protection (Fig 6) .
Bronchial reactions to repeated antigen provocation during the period of testing (up to four months) showed a tendency to hyposensitization in the majority. This seemed to be localized to the bronchial tree because patients showing this effect frequently complained of nasal symptoms, whilst the bronchial challenge tests were being carried out. In only one patient (AS) was there an increase in sensitivity and in only 2 patients (AG and BC) did the response remain fairly constant for two months before the onset of hyposensitization. In 8 of the 9 remaining, this phenomenon was observed right from the start of testing, and in some of them this process was very rapid. Despite this it was possible to demonstrate a protective effect of AH 7079 in 4 of these patients, but the degree of protection could not be assessed. Drug pretreatment by inhibiting the response to antigen might have played some part in this process, although sometimes marked hyposensitization occurred before the use of inhibitors. This was one of the reasons for testing AH 7079 before DSCG in some patients, and after it in others. It should be added, however, that in 6 of the patients included in this study bronchial challenge tests were carried out at weekly intervals, while in the other 6 they were carried out twice a week. Although bronchial hyposensitization seemed to develop more readily in the latter group, which is compatible with our previous experience, the number of patients was too small to allow for a proper conclusion.
In nine of the twelve patients late reactions to bronchial challenge were suspected but regular measurement of expiratory peak flow rate (EPFR) confirmed these reactions in only 5 patients. They were of two distinct types: one occurring within 1-8 hours, and the other later than 24 hours. The latter was uninfluenced by a single-dose pretreatment with either AH 7079 or DSCG (Fig 6) . The late reaction occurring within 1-8 hours seemed to be influenced by drug pretreatment in some patients. On the whole, however, late reactions were too complex to have a proper analysis. In some of the patients cellmediated immunity (delayed-type hypersensitivity) was suggested by a positive lymphocyte stimulation (transformation) test, but there is little doubt nowadays that the latter test, as usually carried out, cannot distinguish between different immunological mechanisms.
(b) Inhibition ofresponse to nasal challenge: Nasal challenge tests were performed by spraying one or more puffs of standard concentrations of antigen extracts directly on to the nasal septum, from nebulizers with an output of 0.015-0.02 ml per shot (McAllen, Assem & Maunsell 1970) . The total amount of antigen required to produce a definite response (irritation, sneezing, blocking and running of the nose) after ten minutes varied from 1 to 50 ,ug of D. pteronyssinus extract and 1 to 50 Noon units of grass pollen extract. A double-blind study was carried out by spraying either a placebo solution or AH 7079 (3 mg/ml), either two minutes before or simultaneously with antigen. The matching placebo solution contained 1 mg/ml tartrazine dye and 0.2 ,ug/ml lignocaine benzyl benzoate. In the case of pretreatment two puffs of placebo solution were sprayed on to one side ofthe nasal septum, and two puffs ofAH 7079 (120 Mg) were sprayed on to the other side. In instances where this treatment was applied simultaneously with antigen a 30 mg/ml solution of the drug or its corresponding placebo solution was ten-times diluted in the antigen solutions. In this case patients requiring more than two puffs of antigen spray (up to six) received proportionately higher amounts of drug (up to 360 Mg).
In the double-blind sequential trial a statistically significant result in favour of AH 7079 was obtained by testing a total of 33 patients (Assem & McAllen 1973) .
Summary
(1) Model studies on anti-allergy drugs have been carried out by making a quantitative comparison between the inhibitory effects of disodium cromoglycate (DSCG) and representatives of a new series of anti-allergy compounds in vitro (DSCG, AH 7079, AH 6556 and AH 7725). DSCG and AH 7079 were compared with regard to their effect on the response of patients with allergic asthma to allergen inhalation. Only AH 7079 was tested for its effect on the response to nasal challenge in patients with allergic rhinitis.
(2) The wide variety of in vitro models of immediate-type allergy has shown that the AH series, though not appreciably more potent in some 34 models, were clearly superior in the antigeninduced histamine release from isolated human leukocytes and in the lymphocyte transformation test.
(3) Asthmatic attacks due to immediate allergic response to experimentally inhaled antigen were inhibited by AH 7079 inhaled shortly before antigen. A dose of 3 mg seemed to be optimal in this test. However, the single dose given did not inhibit late reactions. The relative potency of AH 7079 and DSCG in inhibiting the response to bronchial challenge could not be assessed because of the unusual shape of dose-response curves, particularly of DSCG.
(4) Optimum dose of either inhibitor varied from one patient to another.
(5) Bronchial desensitization due to repeated allergen inhalation posed a big problem in the assessment of the effects of-these inhibitors, and it seems likely that such a problem will be met with in similar studies of other drugs. It also seems possible that the use of inhibitors may enhance the development of bronchial desensitization.
(6) A double-blind trial of AH 7079 in patients with allergic rhinitis showed that this drug also inhibits reactions to nasal challenge with antigen.
(7) Our findings suggest that AH 7079 is a potent anti-allergy drug and that it can protect patients with allergic airways disease against reactions to antigen.
